The development of PARP inhibitors in ovarian cancer: from bench to bedside

Yvette Drew

doi:10.1038/bjc.2015.394

The development of PARP inhibitors in ovarian cancer: from bench to bedside

Br J Cancer. 2015 Dec 15;113 Suppl 1(Suppl 1):S3-9. doi: 10.1038/bjc.2015.394.

Author

Yvette Drew^{1

2}

Affiliations

¹ Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
² Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK.

Abstract

The nuclear enzyme poly (ADP-ribose) polymerase (PARP) represents an important novel target in the treatment of ovarian cancer. This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olaparib (Lynparza), in the treatment of BRCA-mutated ovarian cancer.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Female
Humans
Ovarian Neoplasms / drug therapy*
Poly(ADP-ribose) Polymerase Inhibitors / administration & dosage
Poly(ADP-ribose) Polymerase Inhibitors / metabolism
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*

Substances

Poly(ADP-ribose) Polymerase Inhibitors